Literature DB >> 25362181

Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

Ravit Oren1, Moran Hod-Marco1, Maya Haus-Cohen1, Sharyn Thomas2, Dan Blat3, Nerri Duvshani1, Galit Denkberg4, Yael Elbaz4, Fabrice Benchetrit4, Zelig Eshhar3, Hans Stauss2, Yoram Reiter5.   

Abstract

Adoptive transfer of Ag-specific T lymphocytes is an attractive form of immunotherapy for cancers. However, acquiring sufficient numbers of host-derived tumor-specific T lymphocytes by selection and expansion is challenging, as these cells may be rare or anergic. Using engineered T cells can overcome this difficulty. Such engineered cells can be generated using a chimeric Ag receptor based on common formats composed from Ag-recognition elements such as αβ-TCR genes with the desired specificity, or Ab variable domain fragments fused with T cell-signaling moieties. Combining these recognition elements are Abs that recognize peptide-MHC. Such TCR-like Abs mimic the fine specificity of TCRs and exhibit both the binding properties and kinetics of high-affinity Abs. In this study, we compared the functional properties of engineered T cells expressing a native low affinity αβ-TCR chains or high affinity TCR-like Ab-based CAR targeting the same specificity. We isolated high-affinity TCR-like Abs recognizing HLA-A2-WT1Db126 complexes and constructed CAR that was transduced into T cells. Comparative analysis revealed major differences in function and specificity of such CAR-T cells or native TCR toward the same antigenic complex. Whereas the native low-affinity αβ-TCR maintained potent cytotoxic activity and specificity, the high-affinity TCR-like Ab CAR exhibited reduced activity and loss of specificity. These results suggest an upper affinity threshold for TCR-based recognition to mediate effective functional outcomes of engineered T cells. The rational design of TCRs and TCR-based constructs may need to be optimized up to a given affinity threshold to achieve optimal T cell function.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25362181     DOI: 10.4049/jimmunol.1301769

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

Review 1.  Smart CARs engineered for cancer immunotherapy.

Authors:  Saul J Priceman; Stephen J Forman; Christine E Brown
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

Review 2.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

3.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 4.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

Review 5.  How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.

Authors:  Albert T Gacerez; Benjamine Arellano; Charles L Sentman
Journal:  J Cell Physiol       Date:  2016-06-02       Impact factor: 6.384

Review 6.  Challenges and opportunities of allogeneic donor-derived CAR T cells.

Authors:  Yinmeng Yang; Elad Jacoby; Terry J Fry
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

Review 7.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

8.  Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.

Authors:  Daniel T Harris; Marlies V Hager; Sheena N Smith; Qi Cai; Jennifer D Stone; Philipp Kruger; Melissa Lever; Omer Dushek; Thomas M Schmitt; Philip D Greenberg; David M Kranz
Journal:  J Immunol       Date:  2017-12-29       Impact factor: 5.422

9.  Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.

Authors:  Christopher J Holland; Rory M Crean; Johanne M Pentier; Ben de Wet; Angharad Lloyd; Velupillai Srikannathasan; Nikolai Lissin; Katy A Lloyd; Thomas H Blicher; Paul J Conroy; Miriam Hock; Robert J Pengelly; Thomas E Spinner; Brian Cameron; Elizabeth A Potter; Anitha Jeyanthan; Peter E Molloy; Malkit Sami; Milos Aleksic; Nathaniel Liddy; Ross A Robinson; Stephen Harper; Marco Lepore; Chris R Pudney; Marc W van der Kamp; Pierre J Rizkallah; Bent K Jakobsen; Annelise Vuidepot; David K Cole
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 10.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.